News
04-02-2012, 07:20 AM
Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.
More... (http://www.news-medical.net/news/20120402/Nektar-commences-dosing-in-NKTR-192-Phase-1-clinical-study-for-treatment-of-acute-pain.aspx)
More... (http://www.news-medical.net/news/20120402/Nektar-commences-dosing-in-NKTR-192-Phase-1-clinical-study-for-treatment-of-acute-pain.aspx)